Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

US Patent 11918584 · Granted Mar 5, 2024

Estimated economic value: $184,315,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2025
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Combination therapy including a KRASG12C inhibitor and one or more additional ph2022
Dosing of KRAS inhibitor for treatment of cancers2022
Combination therapy including an MDM2 inhibitor and one or more additional pharm2021
Combination therapy including an MDM2 inhibitor and one or more additional pharm2021